NEW YORK (GenomeWeb News) – Quest Diagnostics completed the sale of its HemoCue diagnostics product business to Danaher company Radiometer for about $300 million. The deal was originally announced in February as part of Quest's plans to divest certain non-core assets to focus on its diagnostic information services business. Quest will use proceeds from the sale to repurchase about $300 million of its shares as part of a buyback program, it said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.